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Methods: Animal models: experimental OA was induced in male Wistar
rats by intra-articular injection of 3mg mono-iodoacetate (MIA) into the
right knee, the left knee served as a control and was injected with
saline (biochemical model, n = 4); A second OA model was used to
verify model speciﬁc macrophage activity, we used the surgical anterior
ligament transection model (ACLT, n = 2). As a positive control, we used a
rheumatoid arthritis (RA) mouse model in which RA was induced into the
right knee by injection of methylated bovine serum albumin (mBSA) after
immunisation (n = 2). In this RA model, activated macrophages are known
to be involved abundantly. 24 hours prior to imaging animals we injected
with radioactive labeled folic acid (111In-DOTA-FA). Images of the animals
were obtained using a dedicated small animal multipinhole SPECT/CT
camera (nano-SPECT/CT, Bioscan inc.). Images were obtained at 3, 27
and 52 days after OA induction.
Results: All three models (RA, ACLT, MIA) showed increased uptake of
the 111In-DOTA-FA, not only in the synovial region of the knee, but also
in the plopliteal and inguinal lymph node regions at 15 27 and 52 days.
However, the uptake of activity was less in the experimental OA models
than in the RA model. The MIA model showed a higher activity rate in the
lymph node regions than was seen in the ACLT-model, in which activated
macrophages seemed to play a more prominent role in the synovium.
(a−d) MPH-SPECT/CT images of a RA-mouse (a) and OA rats (b,c =MIA,
d =ACLT) in frontal plane 3D (a,b) and sagittal plane 2D (c,d). Note the
excess activation of macrophages in the lymphoid tissue in the RA mouse
and less in the MIA rat (red arrows) and the activation in the synovial
tissue (white arrow). The SPECT image is represented in color, the micro-
CT image is in grey.
Conclusions: Macrophage activation in experimental OA could clearly
be monitored by SPECT/CT in combination with a folate tracer. As
expected we found increased activation around the knee area, probably
the synovium, though the amount of activity of macrophages in the
lymphoid system up to the inguinal nodes in experimental OA was not
as expected. This shows that macrophages play not only a local role but
are also involved in a more systemic response to the affected knee. This
response is known in RA, in which macrophages have a (auto-)antigen
presenting role in the lymph-nodes. Though, such a role for OA is not
known. By investigating a surgical as well as a biochemical OA-model
it becomes less likely that there is a direct response of macrophages to
the speciﬁc models, as lymph-node activation was high in both models
till the end of the experiment (7.5 wks). To conclude, in-vivo visualization
of activated macrophages in OA provides more insight in OA etiology,
enables to monitor OA intervention strategies and provides a new imaging
biomarker.
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Purpose: Matrix metalloproteases (MMPs) are thought to be important
factors that mediate cartilage loss in osteoarthritis (OA). Il-1 is a strong
inducer of chondrocyte MMP expression however, a role for Il-1 in OA has
never been clearly demonstrated; therefore other factors may play a roll
in regulating MMP expression and cartilage remodeling. Polymorphisms
identiﬁed in genes from the wnt/b-catenin pathway have been associated
with OA and recently, we found that wnt1-inducible secreted protein-1
(WISP1) was expressed at high levels during experimental OA. The aim of
the present study was to examine WISP1 expression in human OA tissue
and to determine the potential of WISP1 to cause cartilage degradation
independently of Il-1.
Methods: Expression of WISP1, both in human OA synovium and
cartilage was determined by Q-PCR and by immunohistochemistry. To
study the effect of WISP1 on cells we stimulated macrophages and
chondrocytes with recombinant WISP1and assayed the effect on the
induction of cartilage degrading enzymes. An adenoviral vector for WISP1
overexpression was generated, and injected in the murine knee joint of
either control mice or Il-1−/− mice. Subsequently, markers for cartilage
degradation were determined.
Results: WISP1 expression in human tissue was 3 times higher in OA
synovium and over 2 times higher in cartilage, compared to control tissue.
In cartilage of OA patients there was clear expression of WISP1 in
chondrocytes and also located pericellularly in the adjacent extracellular
matrix. WISP1 was not detected in control (post-mortem) cartilage. Stimu-
lation of macrophages with WISP1 for 24 hours resulted in the induction of
MMP-3, MMP-9 and MMP-13, 8-, 5- and 3-fold respectively. Remarkably,
no Il-1 was induced by WISP1. In chondrocytes and ﬁbroblasts, only
MMP-3 was signiﬁcantly induced. Synovial overexpression of WISP1
following WISP1-expressing adenovirus injection into murine knee joints
resulted in strong induction of MMP3, MMP-9, MMP-13, ADAMTS4 and
ADAMTS5 in the synovium (12-, 8-, 2-, 10- and 2-fold), and of MMP-3,
MMP-13 and ADAMTS4 in the cartilage (100-, 12, and 3-fold). Neo-
epitope markers for enzymatic cartilage damage, VDIPEN (MMPs) and
NITEGE (aggrecanases) were signiﬁcantly induced in knee joints, 4 days
after WISP1 overexpression. Control virus did not induce any markers
for cartilage degradation. Interestingly, cartilage damage and expression
of catabolic enzymes were identical in Il-1−/− and wild type mice after
WISP1 overexpression, indicating that WISP1 induces cartilage damage
independently of Il-1.
Conclusions:WISP1 is expressed in human OA synovium and cartilage,
and levels are higher compared to controls. WISP1 is a potent inducer
of several MMPs and overexpression causes cartilage degradation. This
effect on cartilage damage is independent of Il-1. We have identiﬁed a
novel mechanism that may contribute to cartilage loss in OA that works
independently of Il-1.
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Purpose: Chondroitin sulfate (CS) is a natural glycosaminoglycan, cur-
rently employed in osteoarthritis, with a therapeutic effect that has been
partially attributed to a potential antiinﬂammatory action on joint cells. We
have previously reported that CS was capable to reduce the markers of
vascular and systemic inﬂammation in rabbits with a combined model of
aterosclerosis and chronic arthritis (British J Pharmacol, 2008). In this
work, our aim was to explore the effect of the administration of CS on
the sinovial injury and on markers of synovial inﬂammation in rabbits with
this combined model and in synovial cells in culture.
Methods: Chronic arthritis was induced by repeated intraarticular in-
jections of ovalbumin in previously immunized rabbits. Atherosclerosis
was simultaneously induced in these rabbits by maintaining them on a
hyperlipidemic diet after producing a femoral de-endothelization. A group
of these rabbits were treated
prophylactically with CS (100mg/kg/day). At sacriﬁce, pheripheral blood
mononuclear cells (PBMC) and synovial membranes were isolated and
stored for expression studies. A piece of synovial membrane was embed-
ded in parafﬁn for histological examination. In order to study the possible
mechanism of action of CS, we also employed human synovial ﬁbroblast
in culture stimulated with Il-1b in the presence or absence of CS (2mM).
Results: In the PBMC from rabbits with the combined model, CS inhib-
ited the expression of monocyte chemoattractant protein (MCP)-1 and
cyclooxigenase (COX)-2 (determined by quantitative PCR and western
blot) and the activation of the NFkB (studied by mobility shift assay). In
the synovial membrane, CS signiﬁcantly diminished the gene expression
and the protein synthesis of COX-2 and MCP-1 and the histopathological
synovitis score (Krenn scale) in comparison to untreated rabbits. In
fact, in the synovial membrane CS partially prevented the intimal layer
proliferation and the inﬂammatory cell inﬁltration observed in the non-
treated animals. Moreover, in synovial cells in culture, CS presence was
able to inhibit the NFkB activation induced by Il-1b.
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Conclusions: We have demonstrated that treatment with CS is capable
to reduce PBMC inﬂammation in rabbits in which chronic arthritis aggra-
vates vascular lesions associated to atherosclerosis. CS evoked a clear
improvement in the inﬂammatory response of the synovial membrane,
as well as a decrease in the synovial histopathological lesions. Our
results suggest that this drug may have beneﬁcial effects on the treatment
of inﬂammatory synovitis probably acting through the NFkB depending
pathway.
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Purpose: Il-1b and TNF-a are cytokines that have always been grouped
into the pro-inﬂammatory cytokine class. In some pathologic scenarios,
as in apoptotic environment, chondrocytes respond in a different way de-
pending on what cytokine is present. It is not clear the exact mechanisms
by they exercise their different functions in the chondrocyte. The present
study, analyzes the differences in protein expression patterns between
both cytokines in order to understand the development of rheumatic
pathologies.
Methods: Human normal chondrocytes were isolated from cartilage ob-
tained from autopsies without history of joint disease. Chondrocytes were
incubated for 48 hours in basal conditions, with Il-1b (5 ng/ml) or TNF-
a (10 ng/ml), and cellular protein extracts were obtained. A pool of four
patients in each condition, by duplicate, was made and resolved by 2-DE.
Protein spots were visualized with Sypro for comparative analyses or
with Coomassie stain for protein identiﬁcation. Qualitative and quantitative
analysis were made with PD-QUEST software. After that, protein spots
were identiﬁed by mass spectrometry using MALDI-TOF/TOF technology.
Validation of identiﬁed spots was made by real time PCR, western blot
and inmunoﬂuorescence.
Results: Different comparative analyses were made in the spots that
were matched in every member. We compared protein proﬁles between
basal and Il-1b, basal and TNF-a and between Il-1b and TNF-a conditions.
We found a different regulation in the expression ratios of cytoskeleton
proteins, modulation of transcription, metabolism, energy production and
stress responses between basal and Il-1b as well as, basal and TNF-a
stimulated cells. In addition to this, comparing both cytokines, this table
shows the qualitative differences in terms of presence (+) or absence (−),
between Il-1b and TNF-a conditions. Also, quantitative differences were
found in Tryptophanil tRNA synthethase, Translation initiation factor 3,
Interferon-induced GTP-binding protein and Argininosuccinate synthase,
that were up-regulated more than two fold in the TNF-a treated cells,
respect to Il-1b condition. On the other hand, proteins such as Antisense
basic ﬁbroblast growth factor or Triose phosphate isomerise, were down-
regulated in the TNF-a situation with a ratio of 0.4 (where Il-1b=1).
These differences affect principally to metabolic chondrocyte activity,
transcription and protein modiﬁcations.
PROT PAR12 P58 PSB3 PSME2 LDHB ACSL4 PBEF MDHM G3P ENOA MATN ANX5
TNFa/Il-1b −/+ −/+ +/− −/+ −/+ −/+ −/+ −/+ −/+ +/− −/+ −/+
Conclusions: Our studies indicate that the cytokines, Il-1b and TNF-a,
have different protein expression patterns in human normal chondrocytes
in culture. This study will help us to understand the role that each member
plays in pathologic processes that affects chondrocytes.
A37 AGGRECANASE CLEAVAGE IN THE INTERGLOBULAR
DOMAIN OF AGGRECAN IS MARKEDLY ELEVATED IN
ACUTE ARTHRITIS, OSTEOARTHRITIS AND AFTER KNEE
INJURY
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Purpose: Aggrecanase cleavage at the 373Glu-374Ala bond in the inter-
globular domain of aggrecan, releasing N-terminal 374ARGS fragments,
is an early key event in arthritis and joint injuries. Here we quantify the
levels of aggrecan and aggrecan ARGS fragments in synovial ﬂuid from
knee healthy subjects and from patients with acute arthritis, knee injury
and knee osteoarthritis (OA) with the aim of verifying the pathological role
of aggrecanase cleavage at this site.
Methods: Knee synovial ﬂuid (SF) from 26 knee healthy individuals
(REF) and 269 patients were obtained in a cross sectional study. Patient
groups were acute arthritis (AA; n = 48), knee injury (KI; n = 192) and
OA (n = 29). The KI group was divided into three subgroups by time
after injury: 0−8 weeks (KI-1; n = 64), 9−52 weeks (KI-2; n = 58) and
>1 year (KI-3; n = 70). Aggrecan fragments with the N-terminal 374ARGS
were assayed by ELISA using a monoclonal antibody (OA-1). Total
aggrecan content was analyzed by an Alcian blue precipitation method
measuring sulfated glycosaminoglycan (sGAG) and by an ELISA using
the monoclonal antibody 1-F21 recognizing a peptide sequence in the
keratan sulfate domain. Kruskal-Wallis one way analysis of variance on
rank (Dunn’s method) was used for multiple group comparisons; P< 0.05
was considered signiﬁcant. Spearman rank order correlation (rS) was
used for comparisons.
Results: Median concentrations of aggrecan ARGS fragments (pmol/ml
SF) were elevated in all groups compared to the REF (Table I). The largest
elevation (177-fold) was seen in the acute arthritis group, while the knee
injury group had a 13-fold elevation and the OA group a 9-fold elevation.
Subdivision of the knee injury group showed that elevation of the ARGS
concentration in the knee injury group all occurred in the time span of
0−8 weeks after injury (KI-1) which was 130-fold elevated compared to
the reference. The release of ARGS fragments into the synovial ﬂuid
thereafter did not differ from REF. The SF ARGS concentration correlated
positively with the overall aggrecan content measured by Alcian blue
precipitation (rS = 0.687) and by the 1-F21 ELISA (rS = 0.667). In contrast
to the results of the ARGS immunoassay, when using the Alcian Blue
precipitation method only the AA and KI-1 groups differed in aggrecan
concentration from the REF group, and no differences between groups
were seen when using the 1-F21 assay (Table I).
Conclusions: The observed differences in ARGS concentration in syn-
ovial ﬂuid between the diagnostic groups showed that the aggrecanase
cleavage at the 373Glu-374Ala bond in the interglobular domain of ag-
grecan is enhanced in joint pathology, most markedly in acute arthritis
and early after knee injury, but also in knee OA. In contrast to methods
quantifying human SF total aggrecan (e.g. by sGAG measurements),
quantiﬁcation of ARGS fragments generated by aggrecanases is clearly
a more powerful tool in distinguishing healthy from diseased and injured
joints. The ARGS ELISA method could be used for monitoring disease
progression, predicting clinical outcomes and following the effects of
treatment.
Table I: Human SF median concentrations (ranges) of ARGS, sGAG and aggrecan
ARGS ELISA Alcian blue precipitation 1-F21 ELISA
Diagn
groups
n pmol
ARGS/ml
Fold
diff
P < 0.05 n mg
sGAG/ml
Fold
diff
P < 0.05 n mg aggrecan/
ml
Fold
diff
P < 0.05
REF 26 0.5
(0.5−3.3)
1 na 26 61
(5−210)
1 na 22 132
(20−558)
1 na
AA 48 88.5
(0.5−961)
177 Y 47 88
(112−528)
1.44 Y 45 261
(12−1912)
1.98 N
1KI 192 6.6
(0.5−946)
13 Y 191 74
(5−728)
1.21 N 189 104
(0.2−1340)
0.79 N
KI-1 64 64.9
(0.5−946)
130 Y 64 121
(39−728)
1.98 Y 62 178
(44−1340)
1.35 N
KI-2 58 0.5
(0.5−266)
1 N 58 63
(16−317)
1.03 N 57 87
(14−759)
0.66 N
KI-3 70 0.5
(0.5−166)
1 N 69 59
(5−245)
0.97 N 70 87
(0.2−791)
0.66 N
OA 29 4.6
(0.5−318)
9 Y 29 58
(8−201)
0.95 N 29 127
(12−482)
0.96 N
REF, knee healthy reference; AA, acute arthritis; KI, knee injury; KI-1, knee injury subgroup (SF aspiration
0−8 weeks after injury); KI-2, knee injury subgroup (SF aspiration 9−52 weeks after injury); KI-3, knee injury
subgroup (SF aspiration >52 weeks after injury); OA, knee osteoarthritis.
A38 RELATIONSHIPS BETWEEN CARTILAGE MRI MARKERS,
BIOCHEMICAL MARKERS, AND PAIN
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Purpose: The pathogenesis of osteoarthritis (OA) is a complicated line
of events in the whole joint, eventually leading to pain and disability. Pain
is one of the most critical symptoms of osteoarthritis (OA) and a central
clinical end goal. However, the sources of pain are elusive and not well
understood – making treatment development challenging. Furthermore,
precise quantiﬁcation of pain is challenging in clinical trials, causing sur-
rogate markers to be desirable. We investigated the association between
pain and knee cartilage markers from magnetic resonance imaging (MRI)
as well as biochemical markers of bone and cartilage turnover.
